Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
7683-36-5
Molecular formula
C14H16N4O3+2
Molecular weight
288.3 g/mol
Drug class
Oxime antidoteacetylcholinesterase reactivator for organophosphate poisoning
Mechanism of action
Provides an oxime group that can bind to the phosphorylated active site of acetylcholinesterase and promote dephosphorylation before enzyme ageing occurs, restoring cholinesterase activity. Reactivation effectiveness depends on the specific organophosphate and timing.
Indications / reported uses
Adjunctive treatment of poisoning with susceptible organophosphorus compounds, together with atropine, decontamination and supportive care, using the locally authorised product and toxicology protocol.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Obidoxime Environmental Risk Assessment (ERA) (the Obidoxime ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.